These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38402640)

  • 1. Integration of CD4
    Liu G; Jin K; Liu Z; Su X; Xu Z; Li B; Xu J; Liu H; Chang Y; Zhu Y; Xu L; Wang Z; Wang Y; Zhang W
    Cancer Sci; 2024 Apr; 115(4):1306-1316. PubMed ID: 38402640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer.
    Su X; Jin K; Guo Q; Xu Z; Liu Z; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Xu J
    Br J Cancer; 2024 Mar; 130(5):852-860. PubMed ID: 38212482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer.
    Sun M; Zeng H; Jin K; Liu Z; Hu B; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
    Cancer Immunol Immunother; 2022 Jun; 71(6):1497-1506. PubMed ID: 34716763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
    Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
    BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
    Yan S; Zeng H; Jin K; Shao F; Liu Z; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Xu J
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35523436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. POLQ identifies a better response subset to immunotherapy in muscle-invasive bladder cancer with high PD-L1.
    Liu G; Jin K; Liu Z; Su X; Xu Z; Li B; Xu J; Chang Y; Wang Y; Zhu Y; Xu L; Xu J; Wang Z; Liu H; Zhang W
    Cancer Med; 2024 Feb; 13(4):e6962. PubMed ID: 38457207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer.
    Liu Z; Jin K; Zeng H; Shao F; Chang Y; Wang Y; Xu L; Wang Z; Cui X; Zhu Y; Xu J
    Eur J Cancer; 2022 Aug; 171():133-142. PubMed ID: 35717821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
    Yu Y; Zeng H; Jin K; You R; Liu Z; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
    Cancer Immunol Immunother; 2022 Sep; 71(9):2117-2126. PubMed ID: 35041031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
    Liu Z; Zeng H; Jin K; Yu Y; You R; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
    Br J Cancer; 2022 May; 126(9):1310-1317. PubMed ID: 35039625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating molecular subtype and CD8
    Li B; Jin K; Liu Z; Su X; Xu Z; Liu G; Xu J; Liu H; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Zhang W
    Cancer Immunol Immunother; 2024 Mar; 73(4):66. PubMed ID: 38430246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer.
    Shao F; Jin K; Li B; Liu Z; Zeng H; Wang Y; Zhu Y; Xu L; Xu J; Wang Z; Chang Y; Zhang W
    Urol Oncol; 2023 Oct; 41(10):433.e9-433.e18. PubMed ID: 37625906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis.
    Ye R; Zeng H; Liu Z; Jin K; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Wang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
    Cancer Immunol Immunother; 2022 Feb; 71(2):301-310. PubMed ID: 34152439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients.
    Liu C; Liu Z; Jin K; Zeng H; Shao F; Chang Y; Wang Y; Xu L; Wang Z; Zhu Y; Zhang W
    Br J Cancer; 2022 Nov; 127(9):1718-1725. PubMed ID: 35999267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD19
    Jiang Q; Fu Q; Chang Y; Liu Z; Zhang J; Xu L; Zhu Y; Wang Y; Zhang W; Xu J
    Cancer Immunol Immunother; 2019 Jan; 68(1):45-56. PubMed ID: 30259082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
    Komura K; Hirosuna K; Tokushige S; Tsujino T; Nishimura K; Ishida M; Hayashi T; Ura A; Ohno T; Yamazaki S; Nakamori K; Kinoshita S; Maenosono R; Ajiro M; Yoshikawa Y; Takai T; Tsutsumi T; Taniguchi K; Tanaka T; Takahara K; Konuma T; Inamoto T; Hirose Y; Ono F; Shiraishi Y; Yoshimi A; Azuma H
    Mol Cancer; 2023 Nov; 22(1):185. PubMed ID: 37980528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting prognosis and clinical efficacy of immune checkpoint blockade therapy
    Fan B; Zheng X; Wang Y; Hu X
    Pathol Oncol Res; 2023; 29():1611117. PubMed ID: 37082269
    [No Abstract]   [Full Text] [Related]  

  • 17. Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer.
    Benítez R; Yu K; Sirota M; Malats N; Pineda S
    Front Immunol; 2023; 14():986598. PubMed ID: 36817478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin
    Zhou Q; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Liu L; Zhu Y; Xu L; Dai B; Guo J; Xia Y; Wang Y; Xu J
    Oncoimmunology; 2020 Apr; 9(1):1747333. PubMed ID: 33457092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stromal LAG-3
    Zeng H; Zhou Q; Wang Z; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Xu L; Dai B; Guo J; Liu L; Zhu Y; Xu J
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy.
    Eckstein M; Strissel P; Strick R; Weyerer V; Wirtz R; Pfannstiel C; Wullweber A; Lange F; Erben P; Stoehr R; Bertz S; Geppert CI; Fuhrich N; Taubert H; Wach S; Breyer J; Otto W; Burger M; Bolenz C; Keck B; Wullich B; Hartmann A; Sikic D;
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.